Clinical trials: Pathologic Complete Response
Prostate Cancer
Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
This study evaluates the use of chemotherapy with cabazitaxel in addition to abiraterone acetate, prednisone, and leuprolide in neoadjuvant setting prior to radical prostatectomy in patients with high-risk prostate carcinoma.
- Trial name
- ACDC-RP (NCT02543255)
- Testing
- Abiraterone acetate with prednisone, Leuprolide, Cabazitaxel with peg-filgrastim
- Where
- 5 sites in Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Triple Negative Breast Cancer
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
[Background]: Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2 (HER-2).
- Trial name
- NCT02511847
- Testing
- Afatinib
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Gastroesophageal Reflux Disease
Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)
The aim of this study is to evaluate the complete remission rates, endoscopic relapses, study discontinuation rates, and quality of life parameters in patients with erosive GERD.
- Trial name
- NCT00325676
- Testing
- Pantoprazole
- Where
- 45 sites in Brazil, Germany and 2 more
- Volunteers
- 639 people
- Sponsor
- Takeda
Rectal Cancer
Validation of a Predictive Model After Complete Response in Rectal Cancer
Background of the study: Prediction of rectal tumor response after chemoradiotherapy (CRT) might be helpful in individualizing treatment strategies, i.e., selecting patients who need less invasive surgery or another radiotherapy…
- Trial name
- Thunder (NCT00969657)
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht Radiation Oncology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the reciprocal translocation t(9;22). The resulting oncoprotein, bcr-abl is an essential trigger for growth and survival of leukemic cells.
- Trial name
- NiloPost-STIM (NCT01774630)
- Testing
- Nilotinib
- Where
- 10 sites in France
- Volunteers
- 31 people
- Sponsor
- University Hospital, Bordeaux
Breast Neoplasms, Breast Cancer
Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers
A correlation between early changes in the tumor maximum standardized uptake value (SUVmax) on FDG-PET after one or two cycles of neoadjuvant chemotherapy (NAC) and the pathological response after 6 to 8 cycles has been…
- Trial name
- NCT02600442
- Testing
- non interventional study
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rectal Cancers, Pathological Complete Response
Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning
This study aims to develop and validate a robust machine learning-based prediction model utilizing baseline clinical data and magnetic resonance imaging (MRI) features.
- Conditions
- Rectal Cancers, Pathological Complete Response, Neoadjuvant Chemoradiotherapy, Machine Learning
- Trial name
- NCT07509632
- Testing
- No interventions
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Peking University People's Hospital
Invasive Aspergillosis
Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples
Diagnosing invasive pulmonary aspergillosis (IPA) remains a challenge in patients (pts) with hematological malignancies. The clinical significance of testing bronchoalveolar lavage (BAL) samples both with polymerase chain…
- Trial name
- NCT01430663
- Where
- 9 sites in Austria, Germany
- Volunteers
- 87 people
- Sponsor
- Heidelberg University
Rectal Cancer
RadioPathomics Artificial Intelligence Model to Predict nCRT Response in Locally Advanced Rectal Cancer
In this study, investigators utilize a radiopathomics integrated Artificial Intelligence (AI) supportive system to predict tumor response to neoadjuvant chemoradiotherapy (nCRT) before its administration for patients with locally…
- Trial name
- RPAI-pCR (NCT04271657)
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
HER2+ Breast Cancer
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
The goal of this systematic review is to assess the effectiveness of neoadjuvant chemotherapy and Trastuzumab in achieving pathological complete response (pCR) in patients with HER2-positive breast cancer.
- Trial name
- NCT05931042
- Testing
- Trastuzumab
- Where
- Pakistan
- Volunteers
- 1,209 people
- Sponsor
- Rawalpindi Medical College
Leukemia, Myeloid, Philadelphia-Positive
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy.
- Trial name
- NCT00297570
- Testing
- Pegylated Interferon and Imatinib
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Sheba Medical Center
Breast Neoplasms
Diagnosis of Pathological Complete Response by Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer
The study aims to evaluate the ability of representative vacuum-assisted minimal invasive biopsy (VAB) to diagnose pathological complete response (pCR=ypT0) in breast cancer patients after neoadjuvant chemotherapy (NACT).
- Trial name
- NCT02575612
- Testing
- vacuum-assisted biopsy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Leukemia
Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate
RATIONALE: Drugs used in chemotherapy, such as everolimus, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00093639
- Testing
- everolimus, imatinib mesylate
- Where
- United States
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission
The primary aim of this innovative immunotherapeutic study is to determine whether the antileukemic effects seen in our previous phase I/II study can be confirmed in a large cohort of patients and whether dendritic cell…
- Trial name
- WIDEA (NCT01686334)
- Testing
- DC vaccine
- Where
- 8 sites in Belgium
- Volunteers
- 130 people
- Sponsor
- Zwi Berneman
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
The goal of this clinical trial is to evaluate the efficacy and safety of SHR-A1811 plus pertuzumab in combination with or without albumin-paclitaxel neoadjuvant therapy for early or locally advanced HER2-positive breast cancer.
- Trial name
- NCT06927180
- Testing
- SHR-A1811, Pertuzumab, Albumin-Paclitaxel
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Henan Cancer Hospital
COVID-19, SARS-CoV-2
FREEDOM COVID-19 Anticoagulation Strategy
Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era.
- Trial name
- FREEDOM COVID (NCT04512079)
- Testing
- Enoxaparin, Apixaban
- Where
- 21 sites in United States, Brazil and 3 more
- Volunteers
- 3,460 people
- Sponsor
- Valentin Fuster
Endocarditis, Bacteremia
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.
- Trial name
- NCT03148756
- Testing
- Dalbavancin, Standard of Care
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- AbbVie
EUS-FNA, Rectal Cancer
TRUS-FNA For The Prediction Of pCR After Neoadjuvant Treatment In Rectal Cancer
Colorectal cancer is one of the most malignancies worldwide. The dominant clinical research strategy of LARC includes neoadjuvant chemoradiotherapy before radical surgery followed combined with adjuvant treatment.
- Conditions
- EUS-FNA, Rectal Cancer, Pathological Complete Remission
- Trial name
- NCT04939103
- Testing
- TRUS-FNA
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Uterine Cervical Neoplasms, Locally Advanced
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Purpose: To evaluate the efficacy and safety of neoadjuvant treatment with iparomlimab and tuvonralimab (QL1706), a dual PD1and CTLA4 bispecific antibody, in combination with paclitaxel and either cisplatin or carboplatin (TP/TC…
- Trial name
- QUARTZ-CC (NCT07646301)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Sun Yat-sen University
Hepatitis C, Chronic
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
This is an open-label, randomized, comparative, multicenter, 48-week study designed to evaluate the efficacy and safety of combination treatment with pegylated interferon and ribavirin in adult subjects with a diagnosis of…
- Trial name
- NCT00202839
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Ribavirin
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC